Compare AbbVie Inc (ABBV) vs Capital One Financial Corp. (COF) Price & Performance

AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.

Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.

Capital One (COF) trades at $202.89, down 1.09% with a bullish technical outlook despite recent earnings misses. The stock shows strong analyst support with 62.5% buy ratings and a $252 consensus target, representing 24% upside. Recent financials reveal revenue growth to $53.43B in 2025 but declining net margins to 4.59%, while cash flow improved significantly to $18.42B. The company faces regulatory scrutiny and credit risk concerns but benefits from Discover integration and expanding software offerings.

COF presents a compelling risk-reward profile with substantial upside to analyst targets, though investors must weigh strong institutional support against margin pressure and economic sensitivity. The Discover acquisition provides long-term scale advantages, but near-term performance depends on credit quality stability and successful integration execution amid potential recessionary headwinds.